These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22569684)

  • 1. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
    Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
    Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin receptors and downstream substrates associate with membrane microdomains after treatment with insulin or chromium(III) picolinate.
    Al-Qatati A; Winter PW; Wolf-Ringwall AL; Chatterjee PB; Van Orden AK; Crans DC; Roess DA; Barisas BG
    Cell Biochem Biophys; 2012 Apr; 62(3):441-50. PubMed ID: 22101510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
    Bose S; Farah MA; Jung HC; Lee JH; Kim Y
    J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
    Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
    Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
    Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
    J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
    Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
    J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
    Dabroś W; Dziga D; Kordowiak AM
    Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
    Dabroś W; Dziga D; Gryboś R; Kordowiak AM
    Pathol Res Pract; 2000; 196(8):561-8. PubMed ID: 10982019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vanadium on insulin sensitivity and appetite.
    Wang J; Yuen VG; McNeill JH
    Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
    Yuen VG; Orvig C; McNeill JH
    Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
    Bhanot S; Girn J; Poucheret P; McNeill JH
    Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic vanadium compound and membrane interfaces: interface-facilitated metal complex hydrolysis.
    Crans DC; Schoeberl S; Gaidamauskas E; Baruah B; Roess DA
    J Biol Inorg Chem; 2011 Aug; 16(6):961-72. PubMed ID: 21667212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
    Marzban L; Rahimian R; Brownsey RW; McNeill JH
    Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
    Li M; Ding W; Baruah B; Crans DC; Wang R
    J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
    Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
    Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes.
    Pereira MJ; Carvalho E; Eriksson JW; Crans DC; Aureliano M
    J Inorg Biochem; 2009 Dec; 103(12):1687-92. PubMed ID: 19850351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
    Shinde UA; Mehta AA; Goyal RK
    Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
    Yuen VG; Orvig C; McNeill JH
    Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vanadium-containing compounds on membrane lipids and on microdomains used in receptor-mediated signaling.
    Roess DA; Smith SML; Winter P; Zhou J; Dou P; Baruah B; Trujillo AM; Levinger NE; Yang X; Barisas BG; Crans DC
    Chem Biodivers; 2008 Aug; 5(8):1558-1570. PubMed ID: 18729092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
    Cong XQ; Piao MH; Li Y; Xie L; Liu Y
    Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.